Soleno Therapeutics 8/7/2024 Earnings Report $46.13 -1.29 (-2.72%) As of 02/21/2025 04:00 PM Eastern Earnings HistoryForecast Soleno Therapeutics EPS ResultsActual EPS-$0.57Consensus EPS -$0.63Beat/MissBeat by +$0.06One Year Ago EPSN/ASoleno Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASoleno Therapeutics Announcement DetailsQuarterDate8/7/2024TimeAfter Market ClosesConference Call ResourcesPress ReleaseSLNO Earnings HistoryPowered by Soleno Therapeutics Earnings HeadlinesSoleno Therapeutics, Inc. (NASDAQ:SLNO) Receives $71.20 Consensus Target Price from BrokeragesFebruary 12, 2025 | americanbankingnews.comPiper Sandler Keeps Their Buy Rating on Soleno Therapeutics (SLNO)February 1, 2025 | markets.businessinsider.comNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of companies partnering with Nvidia on its latest AI Superproject … Companies we refer to as Nvidia's "Silent Partners" … And they could benefit greatly as well on Feb. 26.February 22, 2025 | Weiss Ratings (Ad)Soleno Therapeutics to Participate in Upcoming February Investor ConferencesJanuary 29, 2025 | globenewswire.comSoleno Therapeutics executives receive pay raises and bonusesJanuary 25, 2025 | msn.comIs Soleno Therapeutics (SLNO) the Top Small Cap Stock to Buy with the Highest Upside Potential?January 13, 2025 | insidermonkey.comSee More Soleno Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Soleno Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Soleno Therapeutics and other key companies, straight to your email. Email Address About Soleno TherapeuticsSoleno Therapeutics (NASDAQ:SLNO), a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.View Soleno Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles The Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance?Is Coinbase Stock a Buy After Earnings?CVS Health: Earnings Beat Ignites Stock RallyQualcomm’s Post-Earnings Dip: A Prime Buying Opportunity? Upcoming Earnings Workday (2/24/2025)Intuit (2/25/2025)American Tower (2/25/2025)Bank of Montreal (2/25/2025)Bank of Nova Scotia (2/25/2025)Public Storage (2/25/2025)NVIDIA (2/26/2025)Synopsys (2/26/2025)Salesforce (2/26/2025)Lowe's Companies (2/26/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
